Trailing the SBF 120, Medincell stock plunges nearly 23% in quarterly decline
The Montpellier-based biopharmaceutical company is losing ground in early afternoon trading, while the SBF 120 advances. The stock is among the most lagging values in the index and extends a downward slide that began several weeks ago.
A decline that extends the quarterly drop against a rising index
Medincell stock loses 2.59% to €22.58, among the strongest declines in the SBF 120, which gains 0.42% at the same time. The previous day, the stock was already among the declining values in the SBF 120. Over three months, it shows a decline of 22.88%, much more pronounced than its -3.92% over the week.
The price is in contact with the 20-day moving average (€22.59) and remains below the 50-day moving average (€23.93, gap of 5.64%) and the 200-day moving average (€24.82, gap of 9.02%). The RSI at 49 is neutral. The support at €21.40 is located approximately 5% below the current price, while the resistance at €24.88 remains distant.
A high valuation and recent developments focused on Teva
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to the consensus of analysts surveyed, the stock trades at approximately 53.8 times the expected earnings for the following fiscal year. The group develops and licenses long-acting injectable treatments, including UZEDY, marketed by Teva. Its partner presented new clinical data on its olanzapine at the Psych Congress, with an FDA decision expected at the end of 2026. This presentation dates from the week of September 15-19.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2025
Key reported figures
Revenue: 25,4 millions d'euros
Net income: -18,4 millions d'euros
Risks mentioned
Impact de l'absence de revenus exceptionnels l'année précédente.
Augmentation prévue des dépenses d'exploitation pour soutenir l'expansion.
Opportunities identified
Lancement commercial de l'Olanzapine LAI prévu au T4 2026.
Croissance continue des redevances UZEDY.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
